{
    "clinical_study": {
        "@rank": "92581", 
        "acronym": "SUSI-CS", 
        "arm_group": {
            "arm_group_label": "Biologic", 
            "description": "Patients on treatment with biologics (infliximab or adalimumab)"
        }, 
        "biospec_descr": {
            "textblock": "Standard blood sampling Serum sampling - trough/antibodies of biological agent"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "In this cross sectional and longitudinal study, patients with inflammatory bowel disease on\n      biological treatment with infliximab or adalimumab will be included.\n\n      After inclusion, the dosage of their existing biological therapy will be adjusted following\n      regular trough-level and antibody-level monitoring, according to a treatment algorithm.\n\n      Disease activity markers, fatigue and QoL will be assessed during the study. The hypothesis\n      is that therapeutic drug monitoring may improve clinical disease outcome after one year of\n      follow-up."
        }, 
        "brief_title": "Stavanger IBD Study - Cross Sectional", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Inflammatory Bowel Disease", 
        "condition_browse": {
            "mesh_term": [
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with inflammatory bowel disease on treatment with infliximab or\n             adalimumab of any duration (at least 3 doses)\n\n        Exclusion Criteria:\n\n          -  Inability to consent\n\n          -  Inability to adhere to treatment protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with inflammatory bowel disease established (minimum 3 doses) on treatment with\n        infliximab or adalimumab"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134054", 
            "org_study_id": "SUSI-CS_1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Therapeutic drug monitoring", 
            "Biological treatment", 
            "IBD"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stavanger", 
                    "country": "Norway", 
                    "zip": "4068"
                }, 
                "name": "Stavanger University Hospital"
            }, 
            "investigator": {
                "last_name": "Lars N Karlsen, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_groups": "1", 
        "official_title": "Stavanger University Hospital IBD Study - a Cross Sectional Longitudinal Study on Patients Treated With Biologics", 
        "other_outcome": {
            "description": "Registration of\nOutpatient visits\nHospital admissions (days)\nSick leave (days)\nVisits at general practitioner due to IBD activity\nEndoscopy due to IBD activity", 
            "measure": "Healthcare resource utilization", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "overall_contact": {
            "email": "tore.bjorn.grimstad@sus.no", 
            "last_name": "Tore B Grimstad, MD, PhD", 
            "phone": "+47 90921650"
        }, 
        "overall_contact_backup": {
            "email": "lars.normann.karlsen@sus.no", 
            "last_name": "Lars N Karlsen, MD", 
            "phone": "+4705151"
        }, 
        "overall_official": {
            "affiliation": "Stavanger University Hospital, Department of Medicine", 
            "last_name": "Tore B Grimstad, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Norway: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Harvey Bradshaw Index <5 Partial Mayo score <=2", 
            "measure": "Clinical remission rate", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134054"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Harvey Bradshaw Index, Partial Mayo Score. Change after therapeutic drug monitoring.", 
                "measure": "Symptom scoring", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "C reactive protein, Fecal Calprotectin. Change after therapeutic drug monitoring.", 
                "measure": "Inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "Assessed by Fatigue severity scale and Visual analogue scale. Change after therapeutic drug monitoring.", 
                "measure": "Fatigue scoring", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }
        ], 
        "source": "Helse Stavanger HF", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Oslo University Hospital Rikshospitalet", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Oslo University Hospital Radiumhospitalet", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Helse Stavanger HF", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}